AU5097099A - Methods and compositions for cancer treatment - Google Patents

Methods and compositions for cancer treatment

Info

Publication number
AU5097099A
AU5097099A AU50970/99A AU5097099A AU5097099A AU 5097099 A AU5097099 A AU 5097099A AU 50970/99 A AU50970/99 A AU 50970/99A AU 5097099 A AU5097099 A AU 5097099A AU 5097099 A AU5097099 A AU 5097099A
Authority
AU
Australia
Prior art keywords
compositions
methods
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50970/99A
Inventor
Vincent Marinkovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5097099A publication Critical patent/AU5097099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18732—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU50970/99A 1998-07-16 1999-07-12 Methods and compositions for cancer treatment Abandoned AU5097099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9308498P 1998-07-16 1998-07-16
US60093084 1998-07-16
PCT/US1999/015716 WO2000003733A1 (en) 1998-07-16 1999-07-12 Methods and compositions for cancer treatment

Publications (1)

Publication Number Publication Date
AU5097099A true AU5097099A (en) 2000-02-07

Family

ID=22236937

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50970/99A Abandoned AU5097099A (en) 1998-07-16 1999-07-12 Methods and compositions for cancer treatment

Country Status (2)

Country Link
AU (1) AU5097099A (en)
WO (1) WO2000003733A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1558648T1 (en) 2002-10-17 2012-05-31 Genmab As Human monoclonal antibodies against cd20
JP5848861B2 (en) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Human monoclonal antibody against CD20
US20150104425A1 (en) * 2006-07-24 2015-04-16 CortControl, Inc. Medical food for high cortisol breast cancer
US20150366941A1 (en) * 2014-06-19 2015-12-24 Cortcontrol Human disease treatment with medical food formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7111160A (en) * 1971-03-09 1972-09-12
WO1980000790A1 (en) * 1978-10-25 1980-05-01 Benzon As Alfred Transfer factor and method for producing same

Also Published As

Publication number Publication date
WO2000003733A1 (en) 2000-01-27

Similar Documents

Publication Publication Date Title
AU2212299A (en) Compositions and methods for the treatment of tumor
EP1066018B8 (en) Hair treatment compositions
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU1296099A (en) Methods and compositions for treating dermatoses
AU1958897A (en) Egf-genistein conjugates for the treatment of cancer
AU2495200A (en) Compositions and methods for the treatment of tumor
HUP0201436A3 (en) Methods and compositions for treating solid tumors
AU4052897A (en) Cancer treatment method
AU6872498A (en) Method and composition for skin treatment
AU2327599A (en) Compositions and methods for treating autoimmune diseases
AU2349399A (en) R-lansoprazole compositions and methods
EP1176964B8 (en) Uses of et743 for treating cancer
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU4215399A (en) Dermatological compositions and methods
AU1772399A (en) Well treatment
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
IL141426A0 (en) Compositions and methods for the treatment of tumor
AU5333298A (en) Compositions and methods for tumour therapy
IL143212A0 (en) Compositions and methods for the treatment of tumor
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU4859399A (en) Compositions and methods for treating papillomavirus-infected cells
AU2342299A (en) Compositions and methods for detecting and treating breast cancer
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase